Ajanta Pharma Limited has informed the stock exchanges that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Paithan, Maharashtra.
The inspection has been classified as Voluntary Action Indicated (VAI), which indicates that objectionable conditions were found but no mandatory corrective actions are required from the agency.
The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from 13th April 2026 to 21st April 2026. The company had previously intimated the stock exchanges regarding the commencement of this inspection on 22nd April 2026.
The disclosure is signed by Gaurang Shah, Sr. VP - Legal & Company Secretary, and is dated 2nd July 2026 with a digital timestamp of 2026.07.02 13:47:49 +05'30'.